About BioSerenity
BioSerenity is an integrated neuroscience platform. From the production of connected medical devices to collaborative telemedicine, it completes the range of care offered in the diagnosis of brain pathologies and adjacent fields such as sleep disorders and cardiology. It enhances current protocols through the appropriate use of artificial intelligence.
Key Figures
9,000
physicians using our services every year to get a neurology, sleep or cardiology remote diagnostic
200
partner hospitals and clinics
60,000
tele-interpretations of electrophysiology examinations in 2023 (EEG, ECG, PSG) performed at the patient’s bedside, at home or in health centers
12
Sleep diagnostic centers performing Polysomnographies, respiratory polygraphy.
Management
Vincent MARCEL
CEO
Samir MEDJEBAR
COO
Simon Liu
CTO
Board of Directors
Jean Schmitt
Managing Partner & President
Jolt Capital
Antoine TRANNOY
General Partner
Jolt Capital
Dan NEWMAN
Operating partner
Jolt Capital
Medical and Scientific Board
Pr Hervé Vespignani
Professor of Neurology, University of Lorraine, France
Chairman of the BioSerenity Medical and Scientific Committee
Pr Sylvie N'Guyen The Tich
Neuropediatrician, Head of Pediatric Neurology Department, Lille University Hospital, France
General Secretary of the French Society of Neuropediatrics
Pr Iona Mindruta
Neurologist, Head of the Epilepsy Monitoring Unit at Bucharest University Hospital, Romania.
Pr Philippe Derambure
Neurologist, Deputy Head of Division and Head of Department, Clinical Neurophysiology – Epilepsy – EEG at Lille Hospital, France.
Pr Louis Maillard
Neurologist, Head of the Epileptology Unit at Nancy University Hospital, France
Pr Nicolas Gaspard
Professor and Head of Neurology Department, Erasmus Hospital, Brussels, Belgium
Timeline
2014
The birth of BioSerenity
Creation of the NEURONAUTE® connected textile at the Paris Brain and Spinal Cord Institute (APHP Pitié-Salpêtrière hospital) to improve diagnosis and monitoring of epilepsy.
Creation of Serenity medical services. First of all, a meeting with Pr Hervé Vespignani, neurologist at Nancy University Hospital who will be at the origin of the launch of the 1st production service & remote interpretation of electroencephalograms at destination hospitals. 30 Technicians and 20 neurologists at the neurological care in hospitals directly at the patient’s bedside!
2016
Closer to patients
2018
Internationalization
Opening of the first offices outside France, in the United States (Atlanta, Boston) and in China.
BioSerenity contributes to France effort to help caregivers during COVID
In response to the government’s call, Sérénité Protection Santé launched a mask production plant in Troyes, dedicated to the production of FFP2 and surgical masks for healthcare professionals, creating nearly 150 jobs and producing millions of FFP2 masks.
Opening of the first offices outside France, in the United States (Atlanta, Boston) and in China.
2020
Production of FFP2 masks
2020
IceCap
Our teams imagine the IceCap® : a single-use EEG headset suitable for all adult patients, which can be fitted in 10 minutes with no need for prior EEG training. A real innovation for medical teams needing this examination. This new step clearly demonstrates the brand’s commitment to to make daily life easier for caregivers!
Creation of BioSerenity Ateliers combining the production of innovative textiles for BioSerenity for the general public & support for companies in prototyping, from industrial design to the conception of specific textiles.
2022
BioSerenity Ateliers
2023
Neuronaute+
Launch of the second version of the Neuronaute EEG acquisition system : the Neuronaute+. More mobile. Smaller. More connected. Thanks to this range, BioSerenity responds to the challenge of medical wandering for electrophysiological care to the patient’s home.
Extension of the IceCap® range with the arrival of the pediatric version. BioSerenity covers all ages from neonatal to adult.
2023
IceCap Neonatal
2023
Jolt Capital+
Confident in the solutions and services developed by BioSerenity to address the problem of misdiagnosis, JOLT capital invests €24 million in BioSerenity.